Different patterns of HIV-1 DNA after therapy discontinuation

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Re, Maria Carla ^a   Vitone, Francesca ^a   Sighinolfi, Laura ^b   Schiavone, Pasqua ^a   Ghinelli, Florio ^b   Gibellini, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA DETERMINATION; DNA VIRUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; PROVIRUS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA VIRUS; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 27244436421     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-69     Document Type: Article

References (31)

1. Brostrom C, Visco-Comandini U, Yun Z, Sonnerborg A: Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. J Infect Dis 1999, 179:1542-1548.
2. Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, Goedert JJ, Hatzakis A, Multicenter Hemophilia Cohort Study Group: Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002, 76:10099-10108.
3. McDermott JL, Giri AA, Martini I, Bono M, Giacomini M, Campelli A, Tagliaferro L, Cara A, Varnier OE: Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 1999, 37:2361-2365.
4. Riva E, Antonelli G, Scagnolari C, Pistello M, Capobianchi MR, Monforte A, Pezzotti P, Dianzani F, I.CO.N.A. Study Group: Human immunodeficiency virus (HIV) DNA load and level of immunosuppression in treatment-naïve HIV-1-infected patients. J Infect Dis 2003, 187:1826-1828.
5. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85.
6. Nickle DC, Shriner D, Mittler JE, Frenkel LM, Mullins JI: Importance and detection of virus reservoirs and compartments of HIV infection. Curr Opin Microbiol 2003, 6:410-416.
7. Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 1997, 350:983-90.
8. Vitone F, Gibellini D, Schiavone P, Re MC: Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J Clin Virol 2005 in press.
9. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997, 94:13193-13197.
10. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-300.
11. Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, Dupon M, Pellegrin JL, Ragnaud JM: Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003, 187:38-46.
12. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
13. Hockett RD Jr, Saag MS, Kilby JM, Sfakianos G, Wakefield TB, Bucy RP: Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR. J Virol Methods 2000, 87:1-12.
14. Gibellini D, Vitone F, Schiavone P, Ponti C, La Placa M, Re MC: Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J Clin Virol 2004, 29:282-9.
15. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-22.
16. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
17. Florence E, Garcia F, Plana M, Fumero E, Castro P, Lopez A, Cruceta A, Gil C, Arnedo M, Miro JM, Pumarola T, Gallart T, Gatell JM: Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. Clin Infect Dis 2004, 39:569-574.
18. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L, Swiss HIV Cohort Study: Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 2004, 18:1951-1953.
19. Gallo RC: New concepts for future control of HIV derived from studies of pathogenesis. Int J Antimicrob Agents 2000, 16:421-423.
20. Oxenius A, Hirschel B: Structured treatment interruptions in HIV infection: benefit or disappointment? Expert Rev Anti Infect Ther 2003, 1:129-139.
21. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234-241.
22. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF: Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001, 98:13288-13293.
23. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected adults and adolescents [http://www.aidsinfo.nih.gov]. October 29, 2004
24. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, Kwok S: PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000, 38:630-634.
25. Hatzakis AE, Touloumi G, Pantazis N, Anastassopoulou CG, Katsarou O, Karafoulidou A, Goedert JJ, Kostrikis LG: Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004, 18:2261-2267.
26. Tierney C, Lathey JL, Christopherson C, Bettendorf DM, D'Aquila RT, Hammer SM, Katzenstein DA: Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003, 187:144-8.
27. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK: Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1. J Infect Dis 2005, 191:1410-1418.
28. Kabamba-Mukadi B, Henrivaux P, Ruelle J, Delferriere N, Bodeus M, Goubau P: Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler realtime PCR. BMC Infect Dis 2005, 21(5):15.
29. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
30. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
31. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, Richman DD: Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000, 14:821-6.